Margaret E. Gatti-Mays

Jan 17, 2025 | oncologynewscentral.com | Arya Roy |Margaret E. Gatti-Mays

At the Oncology Brothers live event, Advancements in Oncology, during SABCS in San Antonio, Dr. Arya Mariam Roy (The Ohio State University Comprehensive Cancer Center) interviewed Dr. Margaret Gatti-Mays, also from The Ohio State University Comprehensive Cancer Center, who served on the Triple-Negative Breast Cancer panel where the importance of the OlympiA trial update was highlighted, emphasizing its compelling survival data and its critical role in guiding treatment decisions for community...

Oct 11, 2024 | onclive.com | Margaret E. Gatti-Mays

Margaret Gatti-Mays MD, MPH, of The James Cancer Hospital at Ohio State University, discusses the available immunotherapy options in triple-negative breast cancer. Margaret Gatti-Mays MD, MPH, of The James Cancer Hospital at Ohio State University, discusses the available immunotherapy options in triple-negative breast cancer.

Apr 16, 2024 | onclive.com | Margaret E. Gatti-Mays

April 16, 2024Margaret E. Gatti-Mays, MD, MPH, FACP, discusses the current use of neoadjuvant chemoimmunotherapy in early-stage triple-negative breast cancer. Margaret E.

Aug 31, 2023 | onclive.com | Margaret E. Gatti-Mays

Margaret E. Gatti-Mays, MD, MPH, FACP, section chief, Breast Medical Oncology, associate professor, Division of Medical Oncology, Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center–James, discusses updated biomarker data from the phase 2 NeoPACT trial (NCT03639948) of neoadjuvant chemoimmunotherapy in triple-negative breast cancer (TNBC).